Yervoy/Zelboraf Combo Trial Fails, But Sequential Study Continues
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Small Phase I melanoma study testing a combination of Zelboraf and Yervoy was closed early due to an unexpectedly high rate of liver toxicity, investigators report in letter to the editor of the New England Journal of Medicine. A sequential study of Yervoy and Zelboraf and other combination studies proceed as planned.
You may also be interested in...
GSK’s Oncology Expansion Heavily Dependent On Dabrafenib, Trametinib
GlaxoSmithKline announced NDA filings for BRAF inhibitor dabrafenib and MEK inhibitor trametinib in metastatic melanoma on Aug. 3. The two compounds represent one-quarter of the company’s novel oncology agents in clinical development, according to the most recent pipeline update.
GlaxoSmithKline Deals One-Two Punch With BRAF/MEK Pair
GSK presented Phase III results for its BRAF inhibitor dabrafenib and its MEK inhibitor trametinib at the American Society of Clinical Oncology annual meeting June 4. But the real excitement is over the just-starting Phase III trial combining the two drugs.
Right Dosing, Scheduling Key To Anticipating Resistance, Creating Synergistic Combos In Drug Development
The art of developing synergistic combinations of novel drugs that can win the race against resistance mutations was much discussed at the American Association for Cancer Research meeting in Chicago March 31 - April 4.